

**Feldmann, Heinrich (NIH/NIAID) [E]**

---

**From:** Hoener, Thomas (NIH/NIAID) [F]  
**Sent:** Wednesday, October 15, 2014 12:57 PM  
**To:** 'Jensen, Victoria M. (CTR)'  
**Cc:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Subject:** RE: Endothelial activation by VP40/GP

Hi Vic,

We have expression plasmids for VP40 and GP1,2, so from my end it would be no problem to send those if Heinz is OK with this (but if I get it right he was the person who contacted you in the first place). We get tons of requests for plasmids right now anyway, mostly for the tetracistronic trVLP system.

I'm not 100% sure what they mean with expression / purification protocols, do they want to produce VLPs? Redacted  
Redacted by agreement

the one who did the endothelial work, so you probably know best...

All the best, Thomas

**From:** Jensen, Victoria M. (CTR) [REDACTED]  
**Sent:** Wednesday, October 15, 2014 10:39 AM  
**To:** Hoener, Thomas (NIH/NIAID) [F]  
**Subject:** FW: Endothelial activation by VP40/GP

Thomas,

These guys reached out to Heinz and I. I tried to get them material from Aldevron (who I ordered from), but there are no stocks left. We're trying to get it from Connie Schmaljohn now. If that all falls, can you help them? I don't really have a dog in the race, I was just trying to help Heinz since he emailed from Monrovia to ask if I could assist. I'm basically out of resources now if Connie can't assist. I won't ask Peter for my old plasmids.

Vic

**From:** [REDACTED]  
**Sent:** Thursday, October 09, 2014 5:49 PM  
**To:** Jensen, Victoria M. (CTR)  
**Subject:** Endothelial activation by VP40/GP

Dr. Wahl-Jensen,

Our laboratory, the Bradner lab, at the Dana-Farber Cancer Institute <http://bradner.dfci.harvard.edu> has a focus on chemical modulation of chromatin structure. Recently we have used models of endothelial cell activation to study cell state changes phenotypically and at the level of genome-wide chromatin structure. We had a paper this week in Molecular Cell on how chromatin active agents can abrogate cell state transitions (attached). With the outbreak of Ebola we are motivated to test our molecules and hypotheses in relevant models of Ebola activation of endothelium.

We therefore read your work with great interest and in particular your 2005 study with Dr. Feldmann on VP40/GP pro-inflammatory activation of endothelium. As a chromatin/chemistry/cancer laboratory, we are highly motivated to work collaboratively. We would like to test a panel of epigenetic molecules from my laboratory on this system to determine whether we can intercept VP40/GP mediated signal transduction in endothelium. We have established relevant endothelial

**Feldmann, Heinrich (NIH/NIAID) [E]**

---

**From:** Jensen, Victoria M. (CTR) [REDACTED]  
**Sent:** Thursday, October 09, 2014 4:06 PM  
**To:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Subject:** FW: Endothelial activation by VP40/GP  
**Attachments:** [REDACTED]

Heinz,

FYI - I emailed these guys back. I will send them protocols and I'm seeing if they can get plasmids from Aldevron with my permission. That will be the easiest.

Vic

**From:** [REDACTED]  
**Sent:** Thursday, October 09, 2014 5:49 PM  
**To:** Jensen, Victoria M. (CTR)  
**Subject:** Endothelial activation by VP40/GP

Dr. Wahl-Jensen,

Our laboratory, the Bradner lab, at the Dana-Farber Cancer Institute <http://bradner.dfc.harvard.edu> has a focus on chemical modulation of chromatin structure. Recently we have used models of endothelial cell activation to study cell state changes phenotypically and at the level of genome-wide chromatin structure. We had a paper this week in Molecular Cell on how chromatin active agents can abrogate cell state transitions (attached). With the outbreak of Ebola we are motivated to test our molecules and hypotheses in relevant models of Ebola activation of endothelium.

We therefore read your work with great interest and in particular your 2005 study with Dr. Feldmann on VP40/GP pro-inflammatory activation of endothelium. As a chromatin/chemistry/cancer laboratory, we are highly motivated to work collaboratively. We would like to test a panel of epigenetic molecules from my laboratory on this system to determine whether we can intercept VP40/GP mediated signal transduction in endothelium. We have established relevant endothelial functional assays in lab and only require the plasmids and protocols for VP40/GP expression, purification and administration.

Would you be willing to provide these reagents for us? We can assist in any way possible to expedite shipping.

We would also be happy to discuss more over the phone.

Regards,

[REDACTED]  
[REDACTED]  
Dana-Farber Cancer Institute  
Department of Medical Oncology

[REDACTED]  
<http://bradnerlab.com>

**Feldmann, Heinrich (NIH/NIAID) [E]**

---

**From:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Sent:** Wednesday, October 15, 2014 1:04 PM  
**To:** Hoenen, Thomas (NIH/NIAID) [F]; [REDACTED]  
**Subject:** Re: Endothelial activation by VP40/GP

We can send the plasmid under an SLA.

**From:** Hoenen, Thomas (NIH/NIAID) [F]  
**Sent:** Wednesday, October 15, 2014 02:57 PM Eastern Standard Time  
**To:** 'Jensen, Victoria M. (CTR)' [REDACTED]  
**Cc:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Subject:** RE: Endothelial activation by VP40/GP

Hi Vic,

We have expression plasmids for VP40 and GP1,2, so from my end it would be no problem to send those if Heinz is OK with this (but if I get it right he was the person who contacted you in the first place) We get tons of requests for plasmids right now anyway, mostly for the tetracistronic trVLP system.

I'm not 100% sure what they mean with expression / purification protocols, do they want to produce VLPs? If that's the case, a simple transfection in 293T cells followed by purification over a sucrose cushion should do them - but you are the one who did the endothelial work, so you probably know best ..

All the best, Thomas

**From:** Jensen, Victoria M. (CTR) [REDACTED]  
**Sent:** Wednesday, October 15, 2014 10:39 AM  
**To:** Hoenen, Thomas (NIH/NIAID) [F]  
**Subject:** FW: Endothelial activation by VP40/GP

Thomas,

These guys reached out to Heinz and I. I tried to get them material from Aldevron (who I ordered from), but there are no stocks left. We're trying to get it from [REDACTED] now. If that all fails, can you help them? I don't really have a dog in the race, I was just trying to help Heinz since he emailed from Monrovia to ask if I could assist. I'm basically out of resources now if [REDACTED] can't assist. I won't ask [REDACTED] for my old plasmids.

Vic

**From:** [REDACTED]  
**Sent:** Thursday, October 09, 2014 5:49 PM  
**To:** Jensen, Victoria M. (CTR)  
**Subject:** Endothelial activation by VP40/GP

Dr. Wahl-Jensen,

Our laboratory, the Bradner lab, at the Dana-Farber Cancer Institute <http://bradner.dlci.harvard.edu> has a focus on chemical modulation of chromatin structure. Recently we have used models of endothelial cell activation to study cell

**Feldmann, Heinrich (NIH/NIAID) [E]**

---

**From:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Sent:** Friday, October 10, 2014 4:24 AM  
**To:** [REDACTED]  
**Subject:** Re: Endothelial activation by VP40/GP

Thanks Vicki.

**From:** Jensen, Victoria M. (CTR) [REDACTED]  
**Sent:** Thursday, October 09, 2014 06:06 PM Eastern Standard Time  
**To:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Subject:** FW: Endothelial activation by VP40/GP

Heinz,

FYI - I emailed these guys back. I will send them protocols and I'm seeing if they can get plasmids from Aldevron with my permission. That will be the easiest.

Vic

**From:** [REDACTED]  
**Sent:** Thursday, October 09, 2014 5:49 PM  
**To:** Jensen, Victoria M. (CTR)  
**Subject:** Endothelial activation by VP40/GP

Dr. Wahl-Jensen,

Our laboratory, the Bradner lab, at the Dana-Farber Cancer Institute <http://bradner.dfc.harvard.edu> has a focus on chemical modulation of chromatin structure. Recently we have used models of endothelial cell activation to study cell state changes phenotypically and at the level of genome-wide chromatin structure. We had a paper this week in *Molecular Cell* on how chromatin active agents can abrogate cell state transitions (attached). With the outbreak of Ebola we are motivated to test our molecules and hypotheses in relevant models of Ebola activation of endothelium.

We therefore read your work with great interest and in particular your 2005 study with Dr. Feldmann on VP40/GP pro-inflammatory activation of endothelium. As a chromatin/chemistry/cancer laboratory, we are highly motivated to work collaboratively. We would like to test a panel of epigenetic molecules from my laboratory on this system to determine whether we can intercept VP40/GP mediated signal transduction in endothelium. We have established relevant endothelial functional assays in lab and only require the plasmids and protocols for VP40/GP expression, purification and administration.

Would you be willing to provide these reagents for us? We can assist in any way possible to expedite shipping.

We would also be happy to discuss more over the phone.

Regards,

[REDACTED]

**Feldmann, Heinrich (NIH/NIAID) [E]**

---

**From:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Sent:** Monday, September 22, 2014 7:59 AM  
**To:** [REDACTED]  
**Subject:** RE: p1 stock

Can you send me a copy (pdf) of that MTA? We may not need a new one.

**From:** [REDACTED]  
**Sent:** Monday, September 22, 2014 6:14 AM  
**To:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Subject:** RE: p1 stock

Heinz,

Is this something different than the MTA that we already have?

[REDACTED]

**From:** Feldmann, Heinrich (NIH/NIAID) [E] (<mailto:feldmannh@niaid.nih.gov>)  
**Sent:** Saturday, September 20, 2014 5:51 PM  
**To:** Menk, Kay (NIH/NIAID) [E]  
**Cc:** 'Jensen, Victoria M. (CTR)'; [REDACTED]  
**Subject:** RE: p1 stock

Kay,

Please prepare a SLA with Vicki Jensen and another one with [REDACTED]

Material: Zaire ebolavirus – Guinea strains (passage 1 tissue culture). The material will be used for in vitro and in vivo research studies. No commercial purpose.

Please communicate with Vicki and Tom on the receiver and authoritative person at their end. You may also have this from previous SLAs.

Thanks,  
Heinz

**From:** Jensen, Victoria M. (CTR) [REDACTED]  
**Sent:** Friday, September 19, 2014 2:40 PM  
**To:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Subject:** RE: p1 stock

Heinz,  
If you can do the SLA with just adding the additional restrictions, why don't we do that? How soon can we get that in place?  
Thanks,  
Vicki

**Feldmann, Heinrich (NIH/NIAID) [E]**

---

**From:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Sent:** Saturday, September 20, 2014 4:51 PM  
**To:** Menk, Kay (NIH/NIAID) [E]  
**Cc:** 'Jensen, Victoria M. (CTR)'; [REDACTED]  
(twgeisbe@UTMB.EDU)  
**Subject:** RE: p1 stock

Kay,

Please prepare a SLA with Vicki Jensen and another one with [REDACTED]

Material: Zaire ebolavirus – Guinea strains (passage 1 tissue culture). The material will be used for in vitro and in vivo research studies. No commercial purpose.

Please communicate with Vicki and [REDACTED] on the receiver and authoritative person at their end. You may also have this from previous SLAs.

Thanks,  
Heinz

**From:** Jensen, Victoria M. (CTR) [REDACTED]  
**Sent:** Friday, September 19, 2014 2:40 PM  
**To:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Subject:** RE: p1 stock

Heinz,  
If you can do the SLA with just adding the additional restrictions, why don't we do that? How soon can we get that in place?  
Thanks,  
Vicki

**From:** Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]  
**Sent:** Wednesday, September 17, 2014 6:34 PM  
**To:** Jensen, Victoria M. (CTR)  
**Subject:** RE: p1 stock

No idea when a shipment could happen. I currently do not have a form2 in place. Does this mean you do not need an SLA with us? If I ship Winnipeg samples to you, you may need an MTA with Winnipeg. Winnipeg's MTAs have been difficult to sign in the past – not sure if that will impact on you. It might be easier to do an SLA with us instead.

Let me know what you want.

**From:** Jensen, Victoria M. (CTR) [REDACTED]  
**Sent:** Wednesday, September 17, 2014 4:28 PM  
**To:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Subject:** p1 stock